Genmark Diagnostics Inc (NASDAQ:GNMK) Sentiment Increased in Q1 2019

Sentiment for Genmark Diagnostics Inc (NASDAQ:GNMK)

Genmark Diagnostics Inc (NASDAQ:GNMK) institutional sentiment increased to 1.32 in 2019 Q1. Its up 0.13, from 1.19 in 2018Q4. The ratio has improved, as 45 institutional investors increased or opened new holdings, while 34 cut down and sold equity positions in Genmark Diagnostics Inc. The institutional investors in our partner’s database now own: 44.67 million shares, down from 46.19 million shares in 2018Q4. Also, the number of institutional investors holding Genmark Diagnostics Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 10 Reduced: 24 Increased: 30 New Position: 15.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $367.26 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

The stock decreased 3.30% or $0.22 during the last trading session, reaching $6.44. About 197,157 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has risen 7.96% since July 14, 2018 and is uptrending. It has outperformed by 3.53% the S&P500.

Analysts await GenMark Diagnostics, Inc. (NASDAQ:GNMK) to report earnings on July, 29. They expect $-0.21 EPS, up 30.00 % or $0.09 from last year’s $-0.3 per share. After $-0.21 actual EPS reported by GenMark Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Millrace Asset Group Inc. holds 2.02% of its portfolio in GenMark Diagnostics, Inc. for 337,022 shares. Cadian Capital Management Lp owns 5.15 million shares or 1.43% of their US portfolio. Moreover, Needham Investment Management Llc has 0.58% invested in the company for 240,500 shares. The Pennsylvania-based Penn Capital Management Co Inc has invested 0.46% in the stock. Hightower Advisors Llc, a Illinois-based fund reported 2.54 million shares.

Since January 1, 0001, it had 0 insider purchases, and 6 insider sales for $216,748 activity.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) Ratings Coverage

Ratings analysis reveals 100% of GenMark’s analysts are positive. Out of 2 Wall Street analysts rating GenMark, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $10 while the high is $12. The stock’s average target of $11 is 70.81% above today’s ($6.44) share price. GNMK was included in 7 notes of analysts from February 21, 2019. The rating was maintained by Needham with “Buy” on Friday, February 22. Canaccord Genuity maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Thursday, February 21 with “Buy” rating.

More notable recent GenMark Diagnostics, Inc. (NASDAQ:GNMK) news were published by: Seekingalpha.com which released: “Nymox Pharmaceutical leads healthcare gainers; Ionis Pharmaceuticals and GenMark Diagnostics among losers – Seeking Alpha” on April 17, 2019, also Seekingalpha.com with their article: “GenMark Diagnostics Starting To Deliver, But Consistency Is A Key Issue – Seeking Alpha” published on July 06, 2018, Globenewswire.com published: “GenMark Diagnostics to Participate in Upcoming Investor Conferences – GlobeNewswire” on May 23, 2019. More interesting news about GenMark Diagnostics, Inc. (NASDAQ:GNMK) were released by: Globenewswire.com and their article: “GenMark Diagnostics Reports First Quarter 2018 Results Nasdaq:GNMK – GlobeNewswire” published on May 01, 2018 as well as Seekingalpha.com‘s news article titled: “Better Execution Leading To Better Valuation For GenMark – Seeking Alpha” with publication date: June 19, 2019.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.